LH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Labcorp Holdings Inc (LH) does not present a strong buy opportunity at this time for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company's financial performance is strong and analysts have raised price targets, the lack of significant upward momentum in technical indicators, hedge fund selling, and neutral insider activity suggest a cautious approach. Additionally, the options data indicates low speculative interest, and the stock's trend analysis shows limited short-term upside potential.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 63.095, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at $290.349 and $297.771, while support levels are at $266.321 and $258.899. However, the stock's candlestick pattern analysis suggests a 60% chance of a -13.34% decline over the next month, which tempers the bullish technical indicators.
Labcorp's collaboration with PathAI to deploy the AISight Dx digital pathology platform is a positive catalyst, enhancing operational efficiency and diagnostic capabilities. The company's strong financial performance in Q3 2025, with revenue, net income, and EPS showing significant YoY growth, also supports a positive outlook.
Hedge funds are selling the stock, with a 676.52% increase in selling activity over the last quarter. Insider activity is neutral, providing no strong support for the stock. Additionally, the stock's trend analysis indicates a potential -13.34% decline over the next month, which could deter immediate investment.
In Q3 2025, Labcorp demonstrated strong financial growth: Revenue increased by 8.58% YoY to $3.56 billion, net income rose by 54.22% YoY to $261.1 million, EPS grew by 55.22% YoY to $3.12, and gross margin improved by 4.68% YoY to 26.82%.
Analysts have raised price targets recently, with JPMorgan increasing its target to $330 and maintaining an Overweight rating. Baird raised its target to $326 with an Outperform rating, and Morgan Stanley maintains a positive bias with a $308 price target. Piper Sandler raised its target to $300 but kept a Neutral rating. Overall, analysts view the stock positively but with some caution.
